We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genome Sequencing Detects Defects in Human Oocytes

By LabMedica International staff writers
Posted on 30 Dec 2013
A safe, accurate, and low-cost method to select genetically normal embryos for the in vitro fertilization (IVF) procedure can increase a couple's chance of producing a healthy child.

Through whole-genome sequencing of individual oocytes, the new method detects chromosomal abnormalities and DNA sequence variations associated with genetic disorders.

Scientists at the Peking University (Beijing, China) collaborating with colleagues at Harvard University (Cambridge, MA, USA) demonstrated genome analyses of single human oocytes using multiple annealing and looping-based amplification cycle (MALBAC)-based sequencing technology. More...
Various procedures are currently available to detect genetic defects in embryos prior to implantation, but these approaches are often invasive, requiring the removal of cells from the growing embryo, and do not simultaneously detect both chromosomal abnormalities and DNA sequence variations associated with genetic disorders.

The scientists developed a method for sequencing the entire genomes of polar bodies, which are cells that arise as a byproduct of egg cell division and often die later on. Because polar bodies are dispensable for human embryonic development, they can be safely removed without harming the embryo. The whole-genome sequencing methods simultaneously detect both types of defects in single human sperm cells, but until now, an analogous approach had not been applied to oocytes, even though chromosomal abnormalities are much more common in egg cells than in sperm cells.

By sequencing the first and second polar bodies, the scientists have provided proof of principle for a low-cost preimplantation genetic screening procedure of selecting fertilized eggs for transfer that are free of maternal aneuploidy and alleles associated with Mendelian diseases. The MALBAC sequencing offers improved resolution and accuracy of simultaneous detection of chromosome abnormality and heterozygous single nucleotide variants associated with Mendelian diseases.

Jie Qiao, MD, a senior author of the study said, “The new method detects chromosomal abnormalities and DNA sequence variations associated with genetic disorders. In this way, we kill two birds with one stone: one set of deep sequencing analysis to avoid two types of genetic problems. Theoretically, if this works perfectly, we will be able to double the success rate of test tube baby technology from 30% to 60% or even more.” The study was published on December 19, 2013, in the journal Cell.

Related Links:

Peking University
Harvard University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Slide Scanner System
NanoZoomer S540MD
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.